This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyamoto, S.
Right arrow Articles by Shumway, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyamoto, S.
Right arrow Articles by Shumway, S. D.

 Previous Article  |  Next Article 

Mol Cell Biol, January 1998, p. 19-29, Vol. 18, No. 1
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Novel Ikappa Balpha Proteolytic Pathway in WEHI231 Immature B Cells

Shigeki Miyamoto,* Bradley J. Seufzer, and Stuart D. Shumway

Program in Cell and Molecular Biology, Department of Human Oncology, University of Wisconsin---Madison, Madison, Wisconsin 53792

Received 22 August 1997/Accepted 8 October 1997

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The Rel/NF-kappa B family of transcription factors is sequestered in the cytoplasm of most mammalian cells by inhibitor proteins belonging to the Ikappa B family. Degradation of Ikappa B by a phosphorylation-dependent ubiquitin-proteasome (inducible) pathway is believed to allow nuclear transport of active Rel/NF-kappa B dimers. Rel/NF-kappa B (a p50-c-Rel dimer) is constitutively nuclear in murine B cells, such as WEHI231 cells. In these cells, p50, c-Rel, and Ikappa Balpha are synthesized at high levels but only Ikappa Balpha is rapidly degraded. We have examined the mechanism of Ikappa Balpha degradation and its relation to constitutive p50-c-Rel activation. We demonstrate that all Ikappa Balpha is found complexed with c-Rel protein in the cytoplasm. Additionally, rapid Ikappa Balpha proteolysis is independent of but coexistent with the inducible pathway and can be inhibited by calcium chelators and some calpain inhibitors. Conditions that prevent degradation of Ikappa Balpha also inhibit nuclear p50-c-Rel activity. Furthermore, the half-life of nuclear c-Rel is much shorter than that of the cytoplasmic form, underscoring the necessity for its continuous nuclear transport to maintain constitutive p50-c-Rel activity. We observed that Ikappa Bbeta , another NF-kappa B inhibitor, is also complexed with c-Rel but slowly degraded by a proteasome-dependent process in WEHI231 cells. In addition, Ikappa Bbeta is basally phosphorylated and cytoplasmic. We thus suggest that calcium-dependent Ikappa Balpha proteolysis maintains nuclear transport of a p50-c-Rel heterodimer which in turn activates the synthesis of Ikappa Balpha , p50, and c-Rel to sustain this dynamic process in WEHI231 B cells.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Proteolysis is one mechanism by which cells irreversibly control protein functions. The functions of many regulatory proteins, such as oncoproteins, tumor suppressors, cell cycle control proteins, and transcription factors, are controlled by modulated proteolysis (14, 41). In the case of Rel/NF-kappa B, a family of transcription factors important for regulation of many cellular functions (5, 58), the proteolytic control is imposed not on the factors themselves but on the associated inhibitor protein, Ikappa B. Thus, an important area of Rel/NF-kappa B studies focuses on the molecular mechanisms of Ikappa B degradation pathways.

Ikappa B comprises a family of related proteins that includes Ikappa Balpha , Ikappa Bbeta , Ikappa Bgamma /p105, Ikappa Bdelta /p100, and Ikappa Bvarepsilon (4). Ikappa B members form trimeric complexes with dimers of Rel/NF-kappa B family members, p50 (NFKB1), p52 (NFKB2), RelA (p65), c-Rel, and RelB (4, 5, 58). Different Ikappa B members preferentially associate with specific Rel/NF-kappa B dimers and sequester them in the cytoplasm (37). Upon stimulation with extracellular signals, such as cytokines, growth factors, chemical stresses, UV or ionizing radiation, bacterial lipopolysaccharide (LPS), or tetradecanoyl phorbol acetate, many Ikappa B members undergo phosphorylation-dependent degradation to release active Rel/NF-kappa B dimers (5, 58). Signal-inducible degradation of Ikappa Balpha , Ikappa Bbeta , and Ikappa Bvarepsilon requires site-specific phosphorylation of serines 32 and 36, 19 and 23, and 157 and 161, respectively (9, 10, 16, 32, 60). These serines are conserved among family members; therefore, the same or similar kinases may be responsible for phosphorylation (4). Phosphorylation serves as a signal for subsequent attachment of multiple 76-amino-acid ubiquitin polypeptides (1, 12, 43). Ubiquitination targets Ikappa Balpha to degradation by the 26S proteasome (12). Consequently, signal-inducible Ikappa B degradation and Rel/NF-kappa B activation pathways can be efficiently blocked by various cell-permeable proteasome inhibitors (5, 58). Extracellular signal and cell type dictate which of coexisting Rel/NF-kappa B/Ikappa B complexes become targeted for Ikappa B degradation and transient or long-term NF-kappa B activation (54, 58, 60). The activated Rel/NF-kappa B dimers migrate into the nucleus, bind to decameric kappa B DNA binding sites, and regulate transcription of a wide variety of genes. These include Rel/NF-kappa B/Ikappa B members (37) and those involved in immune, inflammatory, and acute-phase responses (28). Rel/NF-kappa B proteins may also regulate oxidative stress responses (46), proliferation (17, 27, 49, 50), and apoptosis (7, 56, 59). Thus, Ikappa B degradation is one essential event in signaling pathways leading to Rel/NF-kappa B activation and subsequent target gene activation. To date, degradation by the 26S proteasome is the only known process for Ikappa B degradation in cells (4, 5, 58).

In mouse splenic B cells and B-cell lines, Rel/NF-kappa B activity is constitutively nuclear and is believed to regulate immunoglobulin kappa light chain (Igkappa ) gene transcription (45, 48). The major constitutive dimers in these cells are a p50 homodimer and a p50-c-Rel heterodimer (31, 36). c-Rel contains a C-terminal transactivation domain which p50 lacks (6, 26); therefore, p50-c-Rel is considered to be the major transcriptional activator. In these B cells, the expression of p50/p105, c-Rel, and Ikappa Balpha is augmented, compared to pre-B cells (36), presumably by autoregulation through the kappa B sites in their genes (13, 22, 53). Other Ikappa B members are also expressed in B cells, but the level of Ikappa Bgamma is lower than that in pre-B cells (25, 30). Ikappa Bgamma preferentially blocks the DNA binding of homodimeric p50 protein (30). Coincidentally, the DNA binding of p50 homodimer is increased in B cells. Among the Ikappa B members, Ikappa Balpha is selectively and rapidly degraded in B cells despite its high synthetic rate (34). Ikappa Balpha can efficiently inhibit the DNA binding of p50-c-Rel present in B cells (34). In the present study, we examined this rapid Ikappa Balpha proteolysis and its relationship to constitutive p50-c-Rel activity in WEHI231 murine B cells. Specifically, we examined the role of Ikappa Balpha S32/36 phosphorylation and ubiquitin-proteasome degradation. In addition, we analyzed degradation, basal phosphorylation, and nuclear localization of Ikappa Bbeta in relation to constitutive p50-c-Rel activation. Our results suggest that a novel calcium-dependent but proteasome-independent Ikappa Balpha proteolysis maintains constitutive p50-c-Rel activity in WEHI231 murine B cells.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell culture. WEHI231 cells were maintained in RPMI 1640 medium (Cellgro; Mediatech) supplemented with 10% fetal bovine serum (HyClone Laboratory, Inc.), 5 × 10-5 M beta -mercaptoethanol, 1,250 U of penicillin G (Sigma), and 0.5 mg of streptomycin sulfate (Sigma) per ml in a 5% CO2 humidified incubator (Forma). 70Z/3-CD14 cells were maintained as described above in the presence of 1 mg of G418 (Gibco-BRL) per ml in the medium. The cells were passaged twice weekly before reaching a cell density of 2 × 106 ml.

Chemicals. Calpain inhibitor I (ALLnL), calpain inhibitor II (ALLM), tosylphenylalanine chloromethyl ketone (TPCK), pyrrolidine dithiocarbamate (PDTC), NH4Cl, dimethyl sulfoxide (DMSO), bacterial LPS, and cycloheximide were purchased from Sigma. Calpeptin (ZLnL) was from Calbiochem, and BAPTA-AM was from NovaBiochem. E64-d and ZLLF were generous gifts from K. Hanada (Taisho Pharmaceutical, Japan) and F. Mercurio (Signal Pharmaceutical), respectively. Lactacystin was generously provided by E. J. Corey (Harvard University). The stock solutions were prepared in DMSO at 50 mg/ml or 100 mM (ALLnL, ALLM, calpeptin, and E64-d), 50 mM (tosylleucine chloromethyl ketone [TLCK] and TPCK), 100 mM (PDTC), 4 mg/ml (ZLLF), 30 mM (BAPTA-AM), and 25 mM (lactacystin and 25% DMSO). NH4Cl and cycloheximide were prepared in H2O at 1 M and 10 mg/ml, respectively. LPS was prepared in the growth medium at 1 mg/ml. In every experiment presented, the amount of DMSO was corrected in each sample such that the effect of DMSO was controlled. All stocks were stored in aliquots either at -70 or -20°C.

Cell preparation and Western blotting. All incubations were performed in 1 ml of growth medium in 1.5-ml Eppendorf tubes secured on Labquaker (Barnstead/Thermolyne) which was placed in a 37°C incubator. The samples were continuously mixed by slow rotation for the period described for each experiment. Cells were then pelleted at 13,000 × g for 10 s in an Eppendorf centrifuge, rinsed twice with phosphate-buffered saline (PBS), resuspended in small amounts of PBS, and lysed by addition of 2× Laemmli buffer. The cell samples were immediately boiled for 10 min to inactivate proteases and phosphatases, electrophoresed in sodium dodecyl sulfate (SDS)-10 or 12.5% polyacrylamide gels, electroblotted (Bio-Rad) onto an Immobilon-P nylon membrane (GIBCO), and then incubated with appropriate IgG fractions in PBS containing 5% nonfat dry milk (Carnation), 0.2% Tween 20 (Sigma), and 0.02% sodium azide (Sigma). IgGs against Ikappa Balpha (C21), Ikappa Bbeta (C20), c-Rel (C), RelA (A), and Sp-1 (1C6) were from Santa Cruz Biotechnology. The antibody against lamin B was from MatriTect. Following an overnight incubation, the blots were washed twice with a wash buffer (PBS-0.2% Tween 20) for 30 min each time at room temperature and then further incubated for 2 h with a secondary horseradish peroxidase (HRP)-conjugated donkey anti-rabbit antibody (Amersham), HRP-conjugated protein A (Amersham), or HRP-conjugated donkey anti-mouse antibody (Oncogene Science). The blots were washed twice as above and developed by using the enhanced chemiluminescence (ECL) procedure as specified by the manufacturer (Amersham).

Samples used for coimmunoprecipitation experiments were resuspended in hypotonic buffer A (2) supplemented with various protease and phosphatase inhibitors as described previously (35), the nuclei were removed by centrifugation at 13,000 × g for 10 s, and 4 volumes of co-IP (coimmunoprecipitation) buffer (10 mM Tris-Cl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.4% Nonidet P-40) was added to the supernatants. The protein A-Sepharose and appropriate antibodies for each protein were then added. For nuclear and cytoplasmic partitioning experiments, cells were lysed in hypotonic buffer A in the presence of above-specified protease and phosphatase inhibitors followed by fivefold dilution with the nuclear preparation buffer as described previously (11), and the fractions were separated by centrifugation through a 50% sucrose cushion in the nuclear preparation buffer. The upper supernatant fractions and the pellets formed at the bottom of the sucrose layer represented the cytoplasmic and nuclear fractions, respectively.

In vivo labeling. Appropriate number of cells were rinsed with Met- Cys- RPMI 1640 medium (CellGro), resuspended at 107 cells/ml, and pulse-labeled with [35S]Met-Cys mixture (Amersham) as described previously (34). Cells were then rinsed twice with growth medium without the label and chased for indicated periods. Cells were then pelleted, rinsed twice with PBS, and frozen at -70°C until all samples were terminated. Samples used for immunoprecipitation experiments were resuspended in IP buffer (20 mM Tris-Cl [pH 8.0], 250 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS, protease and phosphatase inhibitors) supplemented with 0.5% SDS, boiled for 10 min, diluted fivefold with IP buffer, and immunoprecipitated as described above. Following washes, the immunoprecipitates were boiled in the presence of 1 mg of bovine serum albumin and 0.5% SDS in IP buffer, diluted fivefold, and reprecipitated for the second time to reduce backgrounds. The immunoprecipitates were rinsed four times with IP buffer, resuspended in 2× Laemmli buffer, boiled for 10 min, and electrophoresed in SDS-10 or 12.5% polyacrylamide gels. The gels were processed as described previously (34). Nuclear and cytoplasmic fractions were prepared as described above, using the 50% sucrose cushion from cell pellets prepared at each time point of the pulse-chase experiments. The gels were exposed to either X-ray film for generation of figures or a PhosphorImager for quantification using the ImageQuant program.

Retrovirus construction and infection. The murine Ikappa Balpha cDNA was cloned into the pLHL-CA retroviral vector as described previously (57). An oligonucleotide (5'-TATACGCGTTATGGCTAGCTACCCATACGACGTCCCAGATTACGCGGACTTAGGATCCGTTAACAAGCTTAGATCTTC-3') containing the hemagglutinin (HA) tag (underlined) (19) and three amino acids at both N and C termini was cloned into the MluI and BglII sites within the multiple cloning sites of the retroviral vector. The resulting vector is pLHL-CAHA. The murine Ikappa Balpha cDNA clone was amplified by PCR, and the product was digested with BamHI and HindIII and cloned into the BamHI and HindIII sites downstream of the HA tag. This cloning procedure generated murine Ikappa Balpha with an N-terminal HA tag in frame with a total of a 15-amino-acid extension. The S32/36A mutant was generated by site-directed mutagenesis using an oligonucleotide (5'-GTGGACGATCGCCACGACGCAGGTCTAGACGCCATGAAGGACGAGGAGTAC-3') which introduced a unique XbaI site along with change of serines 32 and 36 to alanines. The mutant clones were identified by the presence of a unique XbaI site and confirmed by sequencing. The mutant cDNA was then digested with ApaI and HindIII and cloned into ApaI and HindIII sites of the pLHL-CAHA-mIkappa Balpha , replacing the N-terminal wild-type (WT) sequence.

Retrovirus was generated by transient cotransfection of 293 human embryonic kidney cells (grown in Dulbecco's modified Eagle's medium with 10% bovine serum in 0.1% gelatin-coated culture dishes in 10% CO2 incubators) with a retroviral construct and a helper virus, pCLeco (38), followed by coincubation of either 70Z/3-CD14 or WEHI231 cells for 24 h with Polybrene (4 µg/ml) in RPMI 1640 with the above-specified supplements. The infected cells were separated from adherent 293 cells and then selected with hygromycin (1 mg/ml; Boehringer Mannheim). For cloning, cells were diluted immediately following infection, and individual cells were picked under a microscope and grown from a single cell into a mass culture in the presence of hygromycin. The WEHI231 and 70Z/3-CD14 cells stably expressing WT and S32/36A mutant Ikappa Balpha were maintained in the growth medium supplemented with 1 mg of hygromycin per ml.

EMSA. Cell pellets were prepared as described above except that the concentration of cells used for initial incubations was 5 × 106 to 107 /ml. The cell pellets were stored frozen at -70°C until nuclear extract preparation. Nuclear extracts were prepared as described previously (2), and the conditions for the electrophoretic mobility shift assay (EMSA) were as published previously (36). The nature of the inducible and constitutive NF-kappa B complexes in 70Z/3 and WEHI231 cells, respectively, has been previously published (36). The oligonucleotide used was a double-stranded 27-mer containing the Igkappa intronic kappa B site (5'-CTCAACAGAGGGGACTTTCCGAGAGGCCAT-3'). Following electrophoresis in a 4% native acrylamide gel, the gels were dried, exposed to X-ray films, and developed as described above.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Total Ikappa Balpha is rapidly degraded in WEHI231 murine B cells. The p50-c-Rel dimer is constitutively nuclear in WEHI231 murine B cells (36). We previously demonstrated that newly synthesized Ikappa Balpha is rapidly degraded in these cells (34). In contrast, rapid proteolysis of newly synthesized Ikappa Balpha is not seen in 70Z/3 murine pre-B cells. Coincidentally, these pre-B cells lack constitutive NF-kappa B activity. To further address the question of rapid Ikappa Balpha degradation in B cells, we examined the degradation of the total Ikappa Balpha population. We used anti-Ikappa Balpha to probe immunoblots of total cellular proteins from WEHI231 cells treated for various lengths of time with the protein synthesis inhibitor cycloheximide (Fig. 1A). A 70Z/3 cell line expressing human CD14, 70Z/3-CD14 (23), was similarly examined. The results shown in Fig. 1A demonstrate that total Ikappa Balpha turns over more rapidly in WEHI231 (lanes 8 to 14) than 70Z/3-CD14 (lanes 1 to 7) cells. Equivalent loading between samples is shown by the presence of nonspecific protein (Fig. 1B). Although degradation is augmented, the net steady-state level of Ikappa Balpha protein is ~2-fold higher in WEHI231 cells (Fig. 1C; compare lanes 1 and 5) due to an even greater augmentation of synthesis (34). To determine whether this rapid proteolysis is due to the presence of excess free Ikappa Balpha protein, which has a half-life of about 30 min in Cos cells (51), we performed coimmunoprecipitation using antisera against NF-kappa B subunit proteins. We reasoned that if free Ikappa Balpha was produced in a large quantity to account for the overall half-life of about 40 min, then we should be able to detect some Ikappa Balpha protein which was not bound to NF-kappa B subunit proteins at steady state. As shown in Fig. 1D, all detectable Ikappa Balpha coimmunoprecipitated with c-Rel (lanes 1 and 3) and no free Ikappa Balpha was seen (lane 5). These results demonstrate that most, if not all, Ikappa Balpha is bound to c-Rel and suggest that excess free Ikappa Balpha is unlikely to account for faster Ikappa Balpha turnover in B cells (WEHI231) than in pre-B cells (70Z/3-CD14).


View larger version (46K):
[in this window]
[in a new window]
 
FIG. 1.   Ikappa Balpha is associated with c-Rel and undergoes rapid proteolysis in WEHI231 cells. (A) Total Ikappa Balpha degrades faster in WEHI231 cells than in 70Z/3-CD14 cells. The same number of 70Z/3-CD14 and WEHI231 cells (1.4 × 106) were incubated with cycloheximide (20 µg/ml) and terminated at the time points shown. Total cell pellets were dissolved in 2× Laemmli sample buffer and immediately boiled to preserve potentially modified Ikappa Balpha forms. The samples were electrophoresed in SDS-12.5% polyacrylamide gels, transferred to a nylon membrane, and probed with IgG against Ikappa Balpha protein. The protein bands (arrow) were visualized by ECL reaction. (B) Loading control for blot in panel A. The blot in panel A was reprobed with IgG against RelA and developed as described above; a nonspecific band (arrow) is shown. (C) Relative steady-state levels of Ikappa Balpha in WEHI231 and 70Z/3-CD14 cells. Serial dilutions of 70Z/3-CD14 and WEHI231 cells (shown above each lane in cell number) were loaded. Positions of Ikappa Balpha are shown on the left (arrow). (D) Ikappa Balpha is complexed exclusively with c-Rel in WEHI231 cells. WEHI231 cells (106) were lysed in a hypotonic buffer in the presence of various protease inhibitors and phosphatase inhibitors as described in Materials and Methods, and the cytoplasmic fraction was split into two equal fractions. One fraction was immunoprecipitated with antibody against Ikappa Balpha (lane 1), and the unprecipitated supernatant was reimmunoprecipitated to examine the efficiency of the first precipitation (lane 2). The other half of the original fraction was first immunoprecipitated with anti-c-Rel (lane 3). The unprecipitated proteins were then immunoprecipitated with anti-RelA (lane 4), and the same procedure was repeated for final Ikappa Balpha precipitation (lane 5). The immunoprecipitates were electrophoresed in SDS-10% polyacrylamide gels, blotted, and probed with anti-Ikappa Balpha antibody. The Ikappa Balpha band (filled arrow) was visualized by ECL reaction using HRP-conjugated protein A to reduce reactivity with the rabbit Igµ heavy chains used for immunoprecipitation (open arrow).

Rapid Ikappa Balpha degradation is insensitive to proteasome inhibitors. Since 26S proteasome is the only known in vivo Ikappa Balpha protease (4, 5, 58), the requirement of proteasome activity for rapid Ikappa Balpha proteolysis in WEHI231 cells was next examined. We treated WEHI231 cells with cycloheximide and the proteasome inhibitor ALLnL (58). ALLnL poorly inhibited Ikappa Balpha degradation in these cells (Fig. 2A). As a positive control, we showed that ALLnL blocks Ikappa Balpha degradation induced by LPS in pre-B cells (Fig. 2B). We then examined the effects of a highly specific proteasome inhibitor, lactacystin (18). High doses of lactacystin (up to 75 µM) show no detectable inhibitory activity in WEHI231 cells (Fig. 2C) but block the signal-inducible Ikappa Balpha degradation in pre-B cells (Fig. 2D). Pulse-chase experiments also demonstrated that lactacystin (even at 100 µM) is ineffective at blocking Ikappa Balpha degradation in these B cells (Fig. 2E and quantification by PhosphorImager not shown). These results provide evidence for proteasome-independent Ikappa Balpha proteolysis in WEHI231 cells.


View larger version (48K):
[in this window]
[in a new window]
 
FIG. 2.   Proteasome inhibitors fail to block rapid Ikappa Balpha proteolysis in WEHI231 cells. (A) ALLnL only slightly blocks basal Ikappa Balpha turnover. WEHI231 cells were preincubated with various concentrations of ALLnL as shown for 30 min and then treated with cycloheximide (Cx) for an additional 2 h. Cell samples were processed, and Ikappa Balpha (arrow) was visualized. OT, samples terminated prior to addition of inhibitors. (B) ALLnL efficiently blocks LPS-induced Ikappa Balpha degradation in 70Z/3-CD14 cells. 70Z/3-CD14 cells were pretreated with various doses of ALLnL for 30 min and then treated with LPS (1 µg/ml; lanes 2 to 5) for 15 min. Cells were processed, and Ikappa Balpha was visualized. A slight mobility shift of Ikappa Balpha associated with hyperphosphorylation in lanes 3 to 5 is shown by Ikappa Balpha -P. (C) Lactacystin fails to block rapid Ikappa Balpha degradation in WEHI231 cells. WEHI231 cells were pretreated with various doses of lactacystin for 30 min then treated with cycloheximide for 1.5 h followed by Western blot analysis of Ikappa Balpha . (D) Lactacystin is capable of inhibiting LPS-inducible Ikappa Balpha degradation in 70Z/3-CD14 cells. 70Z/3-CD14 cells were preincubated with various doses of lactacystin for 30 min and then stimulated with LPS (1 µg/ml) for 15 min, and the level of Ikappa Balpha was determined. Lane 8 is loaded with half as many untreated WEHI231 cells as a migration control. Hyperphosphorylated Ikappa Balpha (Ikappa Balpha -P) is in lanes 4 to 7. (E) Pulse-chase of Ikappa Balpha in untreated and lactacystin-treated WEHI231 cells. WEHI231 cells (8 × 106) were pulse-labeled with [35S]Met-Cys for 3.5 h, rinsed with excess growth medium, and incubated with either 0.1% DMSO or 100 µM lactacystin (final DMSO concentration, 0.1%) for various periods. OT was taken immediately after addition of DMSO or lactacystin. Cell samples were processed as described in Materials and Methods, and the resulting dry gel was exposed to X-ray films to visualize Ikappa Balpha . Scanning with a PhosophorImager and quantification by ImageQuant show a slight overloading in lanes 5 and 6, but there was no difference of degradation between these two treatment groups. In addition, a proteolytic intermediate (asterisk) was observed in both the control and treated cells. A similar proteolytic intermediate was not seen during LPS-induced Ikappa Balpha degradation (not shown).

S32/36 phosphorylation is not an absolute requirement for rapid Ikappa Balpha proteolysis. Prior phosphorylation at S32/36 is an essential requirement for most signal-inducible Ikappa Balpha degradation pathways (9, 10). This phosphorylation induces a characteristic mobility shift of the Ikappa Balpha protein during polyacrylamide gel electrophoresis (Fig. 2B and D, Ikappa Balpha -P). However, this mobility shift of Ikappa Balpha was not observed in WEHI231 cells treated with proteasome inhibitors (Fig. 2A and C). To determine if S32/36 phosphorylation is an essential requirement for rapid Ikappa Balpha proteolysis in WEHI231 cells, we examined the degradation of an HA epitope-tagged S32/36A Ikappa Balpha mutant. This mutant contains alanines at positions 32 and 36. As a positive control, WT Ikappa Balpha was also expressed in these cells. Both the WT and endogenous Ikappa Balpha proteins are rapidly degraded in control cells (Fig. 3A, lanes 1 to 5). Therefore, the N-terminal HA epitope does not interfere with degradation. The S32/36A mutant and the endogenous Ikappa Balpha protein are also rapidly degraded in a pool of cells stably expressing this mutant protein (Fig. 3A, lanes 6 to 10). Rapid proteolysis of the S32/36A mutant also occurs in nine independent stable clones that express various levels of the S32/36A mutant (Fig. 3B). These results are in sharp contrast to the absolute requirement of the S32/36 phosphorylation sites for LPS-inducible Ikappa Balpha phosphorylation (Fig. 3C, lanes 3 and 6) and degradation (lanes 2 and 5) in pre-B cells. A mutant of Ikappa Balpha with lysine-to-arginine changes at ubiquitination sites, positions 21 and 22 (K21/22R), also degrades efficiently in WEHI231 cells (not shown). Thus, these results demonstrate that rapid Ikappa Balpha proteolysis can occur in the absence of S32/36 phosphorylation and K21/22 ubiquitination in WEHI231 cells.


View larger version (52K):
[in this window]
[in a new window]
 
FIG. 3.   S32/36 phosphorylation of Ikappa Balpha is not required for rapid Ikappa Balpha proteolysis in WEHI231 cells. (A) Both WT and S32/36A mutant Ikappa Balpha degrade in WEHI231 cells. Pooled WT (lanes 1 to 5)- or S32/36A (lanes 6 to 10)-expressing WEHI231 cells were treated with cycloheximide and terminated at different time points. Exogenous Ikappa Balpha proteins are shown by an open arrow, while the endogenous protein is shown by a filled arrow. An asterisk shows a possible proteolytic intermediate. (B) Degradation of the S32/36A mutant in stable clones. Nine independent clones of WEHI231 cells expressing the S32/36A mutant Ikappa Balpha protein were analyzed for the ability to degrade the mutant Ikappa Balpha protein as described above. The open arrow points to the S32/36A mutant, while the filled arrow points to the endogenous Ikappa Balpha protein. An asterisk shows a possible proteolytic intermediate. (C) The endogenous and exogenous WT but not the exogenous S32/36A mutant Ikappa Balpha undergo LPS-induced hyperphosphorylation and degradation in 70Z/3-CD14 cells. 70Z/3-CD14 cells expressing either WT (lanes 1 to 3) or S32/36A (lanes 4 to 6) were treated with LPS (lanes 2, 3, 5, and 6) without (lanes 2 and 5) or with ALLnL (lanes 3 and 6) (50 µg/ml). Cells were processed and blotted with anti-Ikappa Balpha antibody as for Fig. 1A. The positions of exogenous (exo), endogenous (endo), phosphorylated exogenous (exo-p) and phosphorylated endogenous (endo-p) Ikappa Balpha proteins are shown.

Constitutive p50-c-Rel activity is insensitive to proteasome inhibitors. Even though rapid Ikappa Balpha proteolysis cannot be blocked by proteasome inhibitors in WEHI231 cells, constitutive p50-c-Rel activity may require a proteasome-dependent process. For example, proteasome-dependent degradation of other Ikappa B members, such as Ikappa Bbeta or Ikappa Bvarepsilon , may be required (32, 39, 60). To directly examine this possibility, WEHI231 cells were treated with doses of ALLnL and lactacystin for times up to 3.5 h. Although these inhibitors have been shown to efficiently block signal-induced NF-kappa B activation (58), EMSAs demonstrate that neither proteasome inhibitor is able to inhibit constitutive p50-c-Rel activity (Fig. 4A). The control experiments shown in Fig. 4B demonstrate that both proteasome inhibitors efficiently block LPS-inducible NF-kappa B activation in a dose-dependent manner. Thus, like rapid Ikappa Balpha proteolysis, constitutive p50-c-Rel activation is a proteasome-independent process in WEHI231 B cells.


View larger version (46K):
[in this window]
[in a new window]
 
FIG. 4.   Proteasome inhibitors fail to block constitutive p50-c-Rel activity in WEHI231 cells. (A) ALLnL and lactacystin fail to block constitutive p50-c-Rel activity in WEHI231 cells. WEHI231 cells were treated with various doses of ALLnL (lanes 3 to 5) and lactacystin (lanes 6 to 8) or with DMSO (0.2%) alone (lane 2) for 3 h. Nuclear extracts were analyzed by EMSA using the Igkappa kappa B site (see Materials and Methods). Lane 1 contains untreated WEHI231 cells. The positions of p50-c-Rel, p50 homodimer, and free probe are shown on the left. (B) ALLnL and lactacystin efficiently block LPS-inducible NF-kappa B activation in 70Z/3-CD14 cells. 70Z/3-CD14 cells were pretreated with inhibitors and concentrations as indicated for 30 min, followed by stimulation with LPS (1 µg/ml) for 15 min. Lane 1 contains untreated cells. The nuclear extracts were analyzed as described above. The positions of the inducible p50-p65 (RelA) complex and the free probe are shown on left.

Ikappa Balpha is a target of at least two proteolytic processes in WEHI231 cells. The foregoing data demonstrate that rapid Ikappa Balpha proteolysis and constitutive p50-c-Rel activity in WEHI231 cells are mechanistically distinct from known signal-inducible pathways. This may be due to the lack of the signal-inducible pathway or insufficient uptake of proteasome inhibitors. To directly address these possibilities, WEHI231 cells were stimulated with LPS in the presence and absence of proteasome inhibitors. Stimulation of WEHI231 cells with LPS induces modest Ikappa Balpha degradation in 30 min (Fig. 5A; compare lanes 1, 4, and 6 to lanes 2, 5, and 7). Even though the rate of degradation induced by LPS is lower in this cell type than in pre-B cells (Fig. 2B and D), ALLnL can efficiently block this degradation. Additionally, ALLnL induces accumulation of the slower-migrating S32/36 phosphorylated Ikappa Balpha protein (lane 3). Longer exposure shows the accumulation of a high-molecular-weight Ikappa Balpha ladder, consistent with formation of multiubiquitinated Ikappa Balpha proteins (Fig. 5B, lane 3). More pronounced effects of LPS-inducible degradation and proteasome inhibitors can be seen when WEHI231 cells are treated with cycloheximide to eliminate high-level Ikappa Balpha synthesis (not shown). Finally, the S32/36A mutant is resistant to degradation by LPS stimulation (Fig. 5B, lanes 6 and 7) and remains associated with c-Rel (Fig. 5C, lanes 3 and 6). These results demonstrate that the LPS-inducible Ikappa Balpha degradation processes in B (WEHI231) and pre-B (70Z/3-CD14) cells are indistinguishable and dependent on the S32/36 phosphorylation-dependent ubiquitin-proteasome pathway. Furthermore, the uptake of proteasome inhibitors is sufficient to block LPS-stimulated Ikappa Balpha degradation in these cells. Thus, the results demonstrate that Ikappa Balpha is targeted to at least two proteolytic systems, signal-inducible proteasome-dependent and constitutive proteasome-independent systems, in WEHI231 B cells.


View larger version (31K):
[in this window]
[in a new window]
 
FIG. 5.   Inducible Ikappa Balpha degradation requires the S32/36 phosphorylation-dependent ubiquitin-proteasome pathway in WEHI231 cells. (A) Ikappa Balpha degradation induced by LPS in control, WT, or S32/36 WEHI231 cells. WEHI231 cells were treated with LPS (10 µg/ml) for 30 min with (lane 3) and without (other lanes) 30-min pretreatment with ALLnL (50 µg/ml). Similar numbers of cells stably expressing either WT or S32/36A mutant Ikappa Balpha were also stimulated with LPS as described above. Hyperphosphorylated Ikappa Balpha (Ikappa Balpha -P) is shown in lane 3. (B) Longer exposure of the blot in panel A. A high-molecular-weight ladder and a smaller antiserum-reactive band are seen in lane 3. WT Ikappa Balpha is degraded (compare lanes 4 and 5, band labeled Exo.), while S32/36A is not (lanes 6 and 7). (C) Both exogenous and endogenous Ikappa Balpha are complexed with c-Rel in WEHI231 cells. WEHI231 cells expressing WT (lanes 1 to 3) or S32/36A (lanes 4 to 6) were processed for coimmunoprecipitation as described in legend to Fig. 1D. The positions of exogenous (open arrow) and endogenous (filled arrow) proteins are shown on the left.

Calpain inhibitors and calcium chelators selectively block rapid Ikappa Balpha proteolysis in WEHI231 cells. To further distinguish between constitutive and inducible Ikappa Balpha degradation processes in WEHI231 cells, effects of various protease inhibitors were next examined. Our previous study (Fig. 2A) demonstrated that ALLnL, but not lactacystin, slightly inhibits Ikappa Balpha turnover in unstimulated WEHI231 B cells. Since ALLnL can inhibit the activity of calpain, a calcium-dependent cysteine protease, other calpain inhibitors were also examined. The results shown in Fig. 6A (1.5-h treatment) and B (3.5-h treatment) demonstrate that ALLM can also slightly block basal Ikappa Balpha turnover (lane 4). ALLnL and ALLM possess distinct potencies toward 26S proteasome activity (Ki of 0.67 and 28 µM for ALLnL and ALLM, respectively [42]), but they block the activity of calpain equivalently (Ki of 190 and 120 nM for ALLnL and ALLM, respectively [21]). Consequently, their similar effects on Ikappa Balpha degradation suggest that this process may be calpain mediated. Other calpain inhibitors, such as calpeptin (50% inhibitory dose of 52 nM against calpain I) and a cysteine protease inhibitor, E64-d, are also effective at partially inhibiting Ikappa Balpha proteolysis (Fig. 6A and B, lanes 5 and 6, respectively). Higher doses of ALLnL, ALLM, calpeptin, and E64-d are toxic to the cells and do not further inhibit Ikappa Balpha turnover (not shown). Since calpains require calcium for their activity, we also examined the effects of BAPTA-AM, an intracellular calcium chelator, and EGTA, an extracellular calcium chelator (55). BAPTA-AM and EGTA show marked inhibitory activities both in the Western blot assay (Fig. 6A and B) and the pulse-chase assay (Fig. 6D and E). Equivalent doses of calpeptin, E64-d, EGTA, and BAPTA-AM do not affect LPS-stimulated Ikappa Balpha degradation in 70A/3-CD14 cells (Fig. 6C, lanes 5, 6, and 10; results for EGTA not shown). Also, calpeptin, E64-d, and EGTA are incapable of blocking Ikappa Balpha degradation induced by LPS and cycloheximide in WEHI231 cells (not shown). In contrast, the proteasome inhibitors ALLnL, ALLM, and ZLLF block LPS-induced degradation of Ikappa Balpha , resulting in the accumulation of hyperphosphorylated forms in pre-B (Fig. 6C, lanes 3, 4, and 7) and WEHI231 cells (Fig. 5). A lysosomal inhibitor, NH4Cl, is ineffective but TPCK is effective for inhibiting both processes (Fig. 6A and C, lanes 9 and 8, respectively) as reported previously (34, 35). NH4Cl does not block calpain activity, but TPCK does (8). These results demonstrate that calcium chelators and some calpain inhibitors can selectively block high constitutive Ikappa Balpha turnover.


View larger version (35K):
[in this window]
[in a new window]
 
FIG. 6.   Calpain inhibitors and calcium chelators block rapid Ikappa Balpha proteolysis in WEHI231 cells. (A) Calpain inhibitors and calcium chelators block basal Ikappa Balpha turnover in WEHI231 cells. WEHI231 cells were incubated with cycloheximide (Cx; 20 µg/ml) and the inhibitors for 1.5 h prior to Western blot analysis using Ikappa Balpha antibody. The inhibitors used were ALLnL (50 µg/ml), ALLnM (50 µg/ml), calpeptin (10 µg/ml), E64-d (25 µg/ml), ZLLF (2 µg/ml), TPCK (12.5 µg/ml), NH4Cl (30 mM), BAPTA-AM (30µM), and DMSO (0.2%). Lanes 3 to 11 had same final DMSO concentrations. (B) Longer treatment of WEHI231 cells with inhibitors. WEHI231 cells were treated with various inhibitors plus cycloheximide for 3.5 h and analyzed as described above. The concentrations of inhibitors were the same as specified above. EGTA (lane 8) was at 2.5 mM (final concentration). (C) Calpain inhibitors and calcium chelators do not block LPS-inducible Ikappa Balpha degradation in 70Z/3-CD14 cells. 70Z/3-CD14 cells were pretreated with inhibitors at concentrations as in panel A for 30 min and then treated with LPS (1 µg/ml) for 15 min. Ikappa Balpha was visualized as described above, and the positions of Ikappa Balpha (filled arrow) and hyperphosphorylated Ikappa Balpha (open arrow) are shown on the left. Note the presence of Ikappa Balpha -P in lanes 3, 4, and 7. A band seen above the Ikappa Balpha protein is a nonspecific band. (D) Pulse-chase experiment of Ikappa Balpha in WEHI231 cells treated with various inhibitors. WEHI231 cells were pulse-labeled for 2 h, rinsed with growth medium and incubated with 50 µg of ALLnL per ml (lanes 5 to 8) and 30 µM BAPTA-AM plus 1.25 mM EGTA (lanes 9 to 12) or untreated for 15 min. Samples were terminated immediately after addition of inhibitors (lanes 1, 5, and 9). At various time points thereafter, equivalent numbers of cells were terminated for each condition. The DMSO control (lane 13) was treated for a total of 3 h 15 min (equivalent to 3-h time points in other conditions). Ikappa Balpha was immunoprecipitated and visualized as for Fig. 2E. (E) Quantification of Ikappa Balpha bands in panel D. The dried gel was exposed to a PhosphorImager cassette, scanned with a PhosphorImager, and quantified by ImageQuant, and the values were plotted by using the OT values as 100% against time in hours.

Calcium chelators also block constitutive p50-c-Rel activity. We previously showed that TPCK blocks both rapid Ikappa Balpha degradation and constitutive p50-c-Rel activity (34). If rapid Ikappa Balpha proteolysis is involved in constitutive p50-c-Rel activation, inhibitors of rapid but not signal-inducible Ikappa Balpha degradation should also block constitutive p50-c-Rel activity. Thus, we examined the effects of doses of calpeptin, E64-d, and BAPTA-AM with or without EGTA on the level of constitutive p50-c-Rel activity. BAPTA-AM is able to selectively reduce the level of nuclear p50-c-Rel DNA binding in a dose-dependent manner (Fig. 7A, lanes 2 to 6). This inhibitory effect of BAPTA-AM can be augmented by simultaneous addition of EGTA (lanes 8 to 12). EGTA can also inhibit this process alone (compare lanes 1 and 7). This inhibitory effect is not due to direct inhibition of the DNA binding activity, because BAPTA-AM with or without EGTA does not inhibit p50-c-Rel DNA binding activity when directly added to nuclear extracts isolated from untreated WEHI231 cells (Fig. 7B). This inhibitory effect is also not a result of NF-kappa B nuclear transport blockage, because BAPTA-AM with or without EGTA did not block LPS-induced NF-kappa B nuclear transport (Fig. 7C). The effects of BAPTA-AM and EGTA are not only dose dependent but also time dependent, because the level of constitutive p50-c-Rel activity is progressively reduced over the 3-h period examined (Fig. 7D, lanes 2 to 4 and 5 to 7, respectively). Similarly, calpeptin and E64-d can also selectively reduce the level of p50-c-Rel activity, although not as efficiently as BAPTA-AM and EGTA (not shown). These results demonstrate that inhibitors capable of blocking rapid Ikappa Balpha proteolysis can also selectively block constitutive p50-c-Rel activity in murine B cells. Furthermore, there is a correlation between the degree of inhibition of Ikappa Balpha degradation and p50-c-Rel activity in WEHI231 cells.


View larger version (62K):
[in this window]
[in a new window]
 
FIG. 7.   Calcium is essential for the maintenance of constitutive p50-c-Rel activity in WEHI231 cells. (A) EMSA of WEHI231 cells treated with BAPTA-AM with or without EGTA. WEHI231 cells were treated with various doses of BAPTA-AM without (lanes 2 to 6) or with (lanes 8 to 12) EGTA (2.5 mM). Lane 1, DMSO alone (0.2%); lane 7, DMSO plus EGTA; lane 13, without a nuclear extract. Position of the p50-c-Rel heterodimer is shown by the filled arrow, whereas a p50 homodimer is shown by an open arrow. (B) BAPTA-AM and EGTA do not directly block p50-c-Rel DNA binding activity. A nuclear extract prepared from untreated WEHI231 cells was incubated with doses of BAPTA-AM (lanes 2 to 4), EGTA (lane 5), or BAPTA-AM plus EGTA (lanes 6 to 8) for 40 min and analyzed by EMSA. An area of the gel with p50-c-Rel complex is shown (arrow). (C) BAPTA-AM and EGTA do not block LPS-induced p50-RelA binding activity in 70Z/3-CD14 cells. 70Z/3-CD14 cells were treated with doses of BAPTA-AM without (lanes 3 to 5) or with (lanes 7 to 9) EGTA or with EGTA alone (lane 6) and treated with LPS (1 µg/ml) for 15 min, and nuclear extracts were analyzed by EMSA. Lane 1, unstimulated cells; lane 2, DMSO- and LPS-treated cells. An area of the gel with p50-RelA complex is shown (arrow). (D) Time course of inhibition of p50-c-Rel binding in WEHI231 cells by BAPTA-AM and EGTA. WEHI231 cells were treated with either BAPTA-AM (30 µM; lanes 2 to 4) or EGTA (2.5 mM; lanes 5 to 7) for the indicated periods of time. Nuclear extracts were analyzed by EMSA as described above. Lane 1, untreated cells. The filled arrow points to p50-c-Rel, while the open arrow points to p50 homodimer. (E) Pulse-chase of cytoplasmic and nuclear c-Rel protein in WEHI231 cells. WEHI231 cells were pulse-labeled with [35S]Met-Cys for 3.5 h, washed with growth medium, and incubated in growth medium, and equal cell numbers were terminated at time points shown. The cells were then fractionated into cytoplasmic and nuclear pools, and each pool was immunoprecipitated with anti-c-Rel antibody. Cytoplasmic fractions used for immunoprecipitation were one-fourth the level of the nuclear fractions for each time point. The exposure time for nuclear and the cytoplasmic fractions was the same (3 days). Quantification by PhosphorImager demonstrated that the half-life of cytoplasmic c-Rel was >3 h, while that for nuclear c-Rel was 57 min.

Nuclear c-Rel is short-lived. Ikappa Balpha is complexed with c-Rel in the cytoplasm (Fig. 1D) and undergoes rapid degradation. Since inhibition of Ikappa Balpha degradation reduces nuclear p50-c-Rel DNA binding activity in a time-dependent manner (Fig. 7D), this process is associated with the maintenance of constitutive p50-c-Rel activity. Thus, continuous nuclear transport of cytoplasmic p50-c-Rel dimers may be required to maintain nuclear p50-c-Rel activity. If this model is correct, then the nuclear p50-c-Rel complex must have a relatively short half-life to account for the progressive loss of the nuclear DNA binding activity. To examine this possibility, the nuclear half-life of c-Rel protein was measured by pulse-chase experiments. The half-life of the cytoplasmic c-Rel was also measured as an internal control. The cytoplasmic c-Rel has a half-life of more than 3 h (Fig. 7E, lanes 1 to 4). In contrast, the half-life of nuclear c-Rel is only 57 min (lanes 5 to 8; data quantified with a PhosphorImager not shown). This short nuclear half-life correlates with the progressive loss of the p50-c-Rel DNA binding activity seen in Fig. 7D. Consequently, reduced DNA binding activity is likely due to reduced protein levels. Thus, these results suggest that a continuous nuclear transport of c-Rel complex is required to maintain nuclear p50-c-Rel DNA binding activity. They further suggest that p50-c-Rel nuclear transport is maintained by rapid proteolysis of associated Ikappa Balpha in the cytoplasm.

Basal Ikappa Bbeta degradation is slow and proteasome dependent in WEHI231 cells. The results thus far are consistent with the hypothesis that rapid Ikappa Balpha proteolysis in the cytoplasm maintains nuclear p50-c-Rel activity in WEHI231 B cells. If basal Ikappa Bbeta degradation is rapid in unstimulated B cells, it may also significantly contribute to constitutive p50-c-Rel activity. Accordingly, Ikappa Bbeta degradation has been suggested to regulate prolonged and constitutive NF-kappa B activities (32, 54). To directly examine this possibility, the level of Ikappa Bbeta degradation and its proteasome dependence were examined in unstimulated WEHI231 cells. The pulse-chase experiment shown in Fig. 8A and quantification shown in 8B demonstrate that the half-life of Ikappa Bbeta was >3 h, much longer than that of Ikappa Balpha (~40 min [Fig. 6E]). The different degradation levels of Ikappa Balpha (rapid) and Ikappa Bbeta (slow) are not due to associated Rel/NF-kappa B proteins, because most Ikappa Bbeta is also found complexed with c-Rel (Fig. 8C). To determine if the difference of degradation is due to the different protease systems, the effect of the proteasome-specific inhibitor lactacystin was examined. Figure 8D shows a Western blot analysis demonstrating that lactacystin can efficiently block basal Ikappa Bbeta degradation over a 3-h period (compare lanes 2 to 4 and 5 to 7). The dose response shown in Fig. 8E demonstrates that relatively low doses (15 to 20 µM) of lactacystin are sufficient to completely block basal Ikappa Bbeta degradation (lanes 5 and 6). These results demonstrate that both Ikappa Bbeta and Ikappa Balpha are associated with c-Rel but basal Ikappa Bbeta degradation is proteasome dependent in WEHI231 cells whereas Ikappa Balpha degradation is not.


View larger version (57K):
[in this window]
[in a new window]
 
FIG. 8.   Ikappa Bbeta is complexed with c-Rel and degraded slowly by the proteasome-dependent pathway in WEHI231 cells. (A) Pulse-chase of Ikappa Bbeta in WEHI231 cells. WEHI231 cells were pulse-labeled with [35S]Met-Cys for 3.5 h and chased with growth medium for the indicated periods. The labeled Ikappa Bbeta protein was immunoprecipitated with anti-Ikappa Bbeta antibody in the presence of various protease inhibitors and phosphatase inhibitors as described in Materials and Methods. The position of Ikappa Bbeta is shown by the arrow, and the molecular weight markers are shown on the right. (B) Quantification of Ikappa Bbeta by PhosphorImager. The gel in panel A was exposed to a PhosphorImager, and Ikappa Bbeta bands were quantified. The value at the start of the chase (OT) was used as 100%, and the fractions remaining were plotted against time. The half-life was slightly greater than 3 h. (C) Ikappa Bbeta is associated with c-Rel in WEHI231 cells. Coimmunoprecipitation and Western blotting were performed as for Fig. 1D. The blots were first incubated with HRP-protein A in the presence of sodium azide to saturate the Igµ reactivity. Sodium azide inactivated the HRP activity of HRP-protein A bound to the Igµ heavy chain. The blot was then washed extensively, incubated with anti-Ikappa Bbeta antibody, rinsed, incubated with HRP-protein A without sodium azide, and developed by ECL. No Igµ chain is visible in the blot shown. The arrow points to the Ikappa Bbeta band. (D) Time course of lactacystin-mediated inhibition of basal Ikappa Bbeta degradation in WEHI231 cells. WEHI231 cells were treated with cycloheximide (20 µg/ml) and lactacystin (25 µM) for the indicated periods of time, and the Ikappa Bbeta was detected by Western blotting and ECL reaction using HRP-conjugated goat anti-rabbit antibody. (E) Dose response of lactacystin-mediated inhibition of basal Ikappa Bbeta degradation in WEHI231 cells. WEHI231 cells were treated with cycloheximide (Cx; 20 µg/ml) and lactacystin at doses shown for 3 h, and Ikappa Bbeta was detected as described above.

Ikappa Bbeta is basally phosphorylated and cytoplasmic in WEHI231 cells. Prolonged activation of NF-kappa B has been suggested to involve production of hypophosphorylated Ikappa Bbeta which shields NF-kappa B from Ikappa Balpha proteins and allows nuclear transport of NF-kappa B (52). To examine if such hypophosphorylated nuclear Ikappa Bbeta is constitutively expressed in WEHI231 cells, we compared the forms (slower-migrating phosphorylated versus faster-migrating hypophosphorylated) and subcellular localization (nuclear versus cytoplasmic) of Ikappa Bbeta in unstimulated WEHI231 B cells. 70Z/3-CD14 pre-B cells were also analyzed as a control. There is no difference in level and form of Ikappa Bbeta in these two cell types (Fig. 9A), suggesting that hypophosphorylated Ikappa Bbeta is not present at augmented level in WEHI231 cells. The absence of mobility difference between Ikappa Bbeta in these cell types is not technical, because the faster-migrating hypophosphorylated Ikappa Bbeta protein can be detected when pre-B cells are stimulated with LPS for prolonged periods (Fig. 9B). Furthermore, Ikappa Bbeta is mostly cytoplasmic in unstimulated WEHI231 cells (Fig. 9C, lanes 7, 9, and 11) as in 70Z/3-CD14 cells (lanes 1, 3, and 5), further arguing against the presence of significant level of constitutively nuclear hypophosphorylated Ikappa Bbeta protein. In contrast, two nuclear proteins, Sp-1 and lamin B, are seen only in the nuclear fractions, demonstrating that the cytoplasmic/nuclear fractionation is complete in these experiments. These results together with the results shown in Fig. 8 suggest that Ikappa Bbeta is not a regulator of constitutive p50-c-Rel activity in WEHI231 immature B cells.


View larger version (50K):
[in this window]
[in a new window]
 
FIG. 9.   Level, migration pattern, and subcellular localization of Ikappa Bbeta are the same in WEHI231 cells as in 70Z/3-CD14 cells. (A) Steady-state level of Ikappa Bbeta in WEHI231 and 70Z/3-CD14 cells. The Western blot shown in Fig. 1C was also probed with anti-Ikappa Bbeta antibody to examine the relative level of Ikappa Bbeta protein (arrow). Samples were as in Fig. 1C. (B) Hypophosphorylated Ikappa Bbeta produced following prolonged stimulation of 70Z/3-CD14 with LPS. 70Z/3-CD14 cells were treated with LPS (1 µg/ml) for up to 8 h. Equal fractions of cells were terminated at each time point and analyzed by Western blotting using anti-Ikappa Bbeta antibody. The filled arrow shows basally phosphorylated Ikappa Bbeta , while the open arrow points to newly synthesized hypophosphorylated Ikappa Bbeta (lanes 4 to 6). (C) Ikappa Bbeta is cytoplasmic in both WEHI231 and 70Z/3-CD14 cells. Three sets of 70Z/3-CD14 and WEHI231 cells were fractionated into cytoplasmic (C) and nuclear (N) fractions independently as described in Materials and Methods. The resulting fractions were analyzed by Western blotting using anti-Ikappa Bbeta antibody. (D) Sp-1 and lamin B are nuclear. The blot in panel C was reprobed with antibodies against nuclear proteins Sp-1 (open arrow) and lamin B (closed arrow). The bands were visualized with HRP-conjugated anti-mouse antibody followed by ECL reaction. An asterisk points to an unknown protein which is exclusively localized in the cytoplasmic fraction.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this study, we present several lines of evidence for a novel Ikappa Balpha degradation process that coexists with the well-characterized S32/36 phosphorylation-K21/22 ubiquitination-proteasome pathway (Fig. 10A). We suggest a model (Fig. 10B) in which continuous nuclear transport of p50-c-Rel dimer is induced by a high-level basal degradation of associated Ikappa Balpha protein. This continuous nuclear transport counterbalances the short half-life of nuclear c-Rel complex in WEHI231 cells. The constitutive p50-c-Rel presumably activates transcription of genes encoding Ikappa Balpha , c-Rel, and p50 to replace the degraded pool for the maintenance of this dynamic cycle. We further suggest that rapid Ikappa Balpha proteolysis requires free calcium, likely imported from outside the cell.


View larger version (42K):
[in this window]
[in a new window]
 
FIG. 10.   Signal-inducible and constitutive Rel/NF-kappa B activation pathways in murine B cells. (A) A signal-inducible NF-kappa B activation pathway in 70Z/3-CD14 pre-B cells. The NF-kappa B activation pathway induced by extracellular stimuli involves activation of a specific Ikappa Balpha kinase resulting in site-specific phosphorylation at serine residues 32 and 36. This phosphorylation event signals the multiubiquitination event primarily at lysine residues 21 and 22 by a ubiquitin-conjugating enzyme system, E1-E2-E3 (14). Finally, the multiubiquitinated Ikappa Balpha protein while still complexed with NF-kappa B is then selectively and extensively degraded by the 26S proteasome complex. The liberated NF-kappa B migrates into the nucleus and regulates target genes, including that of Ikappa Balpha . If an activating signal is terminated or downregulated, the newly synthesized Ikappa Balpha will terminate the NF-kappa B activity, resulting in transient NF-kappa B activation. Extracellular signals can also induce degradation of Ikappa Bbeta , resulting in prolonged NF-kappa B activation. (B) Constitutive p50/c-Rel activation pathway in WEHI231 cells. This pathway is a novel Rel/NF-kappa B activation pathway which is distinct from the conventional signal-inducible pathway shown in panel A. This constitutive pathway does not require the S32/36 phosphorylation or the ubiquitin-proteasome pathway. It likely depends on high-level constitutive Ikappa Balpha degradation. This degradation requires free calcium, likely maintained by continuous influx through a calcium channel. Continuous Ikappa Balpha degradation allows continuous nuclear transport of p50-c-Rel complex, which has a relatively short half-life of only 1 h in the nucleus. p50-c-Rel then activates the transcription of genes encoding Ikappa Balpha , c-Rel, and p50/p105 to replenish the degrading pools.

Ikappa Balpha is a target of two distinct proteases, constitutive proteasome-independent protease and the signal-inducible 26S proteasome. Rel/NF-kappa B activation induced by a wide variety of extracellular signals requires proteolysis of the associated Ikappa Balpha by the phosphorylation-dependent ubiquitin-proteasome pathway (reviewed in references 4, 5, and 58). This conclusion is supported by evidence showing that (i) various proteasome inhibitors prevent Ikappa Balpha degradation, (ii) the stabilized Ikappa Balpha is hyperphosphorylated at S32/36 and multiubiquitinated, (iii) S32/36A phosphorylation site mutant is resistant to signal-inducible ubiquitination and degradation, (iv) K21/22R mutant allows signal-inducible S32/36 phosphorylation but retards ubiquitination and degradation, (v) the modified forms of Ikappa Balpha are still bound to NF-kappa B, (vi) proteasome inhibitors also block Rel/NF-kappa B appearance in the nucleus, and finally (vii) an S32/36A mutation or deletion of the N-terminal phosphorylation and ubiquitination sites produces a dominant-negative mutant of Ikappa Balpha that is capable of preventing Rel/NF-kappa B activation induced by many extracellular signals. The only reported exception thus far is NF-kappa B activation following exposure to hypoxia-reoxygenation, which induces Ikappa Balpha phosphorylation at tyrosine 42 and dissociation from NF-kappa B without degradation (24).

In the present study, we used many of these criteria to test whether rapid Ikappa Balpha proteolysis in unstimulated WEHI231 cells is a result of constitutive activation of a signal-inducible degradation pathway. Our results demonstrate that high-level constitutive Ikappa Balpha proteolysis is not mediated by a phosphorylation-ubiquitin-proteasome pathway. Since this process involves degradation of Ikappa Balpha protein without a shift of mobility of Ikappa Balpha in polyacrylamide gel electrophoresis, it is also not a tyrosine phosphorylation-mediated event (24). Additionally, it is not due to overproduction of free Ikappa Balpha protein, which degrades rapidly through a phosphorylation-ubiquitination-independent but proteasome-dependent pathway in HeLa cells (29). Rapid degradation of free Ikappa Balpha also requires basal phosphorylation in the C-terminal PEST sequence (47). It is not known whether this basal PEST phosphorylation is required for high turnover in WEHI231 cells. Although constitutive Ikappa Balpha degradation cannot be inhibited by different proteasome inhibitors, the proteasome-dependent pathway can be induced by LPS (with or without cycloheximide) stimulation of WEHI231 cells. Thus, constitutive Ikappa Balpha proteolysis in WEHI231 cells represents a novel Ikappa Balpha degradation pathway which is present together with the signal-inducible pathway. Identification of amino acid sequence requirements, such as the C-terminal PEST sequence and the basal phosphorylation sites, for constitutive Ikappa Balpha degradation in WEHI231 cells will help to further define this novel Ikappa Balpha degradation pathway.

Protease(s) responsible for rapid Ikappa Balpha proteolysis in WEHI231 cells. What is the protease(s) responsible for constitutive Ikappa Balpha degradation in WEHI231 cells? This degradation process cannot be prevented by lysosomal or proteasome inhibitors. This degradation pathway is, however, sensitive to various inhibitors of calpains. Calpains are calcium-dependent cysteine proteases that play important physiological roles, including those for platelet functions (15). Calpains are also associated with a number of pathological conditions, such as ischemia, cataract, muscular dystrophy, and arthritis (15, 44). There are two major forms of calpains, calpain I (µ-calpain) and calpain II (m-calpain). Either or both can be found in the cytoplasm of most mammalian cells (15). Calpain activity can be blocked by high levels of cell-permeable inhibitors, such as ALLnL, ALLM, and calpeptin, as well as cysteine protease inhibitors, such as leupeptin (ALLR) and E64-d (15, 33). Additionally, removal of free calcium can also block in vivo calpain activity. We have shown that high basal Ikappa Balpha degradation is blocked by calpain inhibitors. The rank order of inhibitor potency against Ikappa Balpha proteolysis in WEHI231 cells is BAPTA-AM and EGTA > calpeptin and E64-d > ALLnL and ALLM. These inhibitors may directly modulate the activity of the Ikappa Balpha protease, or they may inhibit an upstream event involved in activation of the protease. These results nevertheless suggest a potential role for calpain in high constitutive Ikappa Balpha degradation in WEHI231 cells.

Rapid Ikappa Balpha proteolysis maintains continuous nuclear transport of p50-c-Rel to counterbalance short-lived nuclear p50-c-Rel complex. We hypothesized that high Ikappa Balpha proteolysis in unstimulated B cells is responsible for the maintenance of constitutive p50-c-Rel activity (34). This hypothesis predicts that conditions which prevent high basal Ikappa Balpha degradation should also block constitutive p50-c-Rel activity. Additionally, conditions that fail to block the former would not inhibit the latter. Consistent with this hypothesis, proteasome inhibitors or lysosomal inhibitors fail to block Ikappa Balpha turnover and also p50-c-Rel activity. In contrast, calcium chelators and some calpain inhibitors inhibit Ikappa Balpha degradation and constitutive p50-c-Rel activity. Additionally, there is a correlation between the effectiveness of these inhibitors for blocking Ikappa Balpha degradation and inhibiting constitutive p50-c-Rel activity. These results strongly suggest a causal relationship between high basal Ikappa Balpha degradation and constitutive p50-c-Rel activity in WEHI231 cells. However, it is also possible that rapid Ikappa Balpha degradation is a mechanistically unrelated paralleling event and that its inhibition increases the relative level of Ikappa Balpha resulting in artificial blockage of constitutive p50-c-Rel activity.

Inhibition of Ikappa Balpha degradation reduces nuclear p50-c-Rel activity in a time-dependent manner. Maximum loss of p50-c-Rel activity in the nucleus may require 3 to 4 h, depending on the inhibitors used. This time lag may be due to a slow inactivation of the existing nuclear p50-c-Rel complex. Correspondingly, the progressive loss of p50-c-Rel DNA binding activity correlates with the half-life of nuclear c-Rel protein. The short half-life of nuclear c-Rel is not due to inhibition by nuclear Ikappa Balpha protein, since none is detected in WEHI231 nuclei. Therefore, this inactivation mechanism appears distinct from the autoregulatory mechanism where excess free Ikappa Balpha enters the nucleus and rapidly shuts off an otherwise long-lasting NF-kappa B activity (3). It is of interest to determine if the loss of nuclear c-Rel is due to degradation in the nucleus or to cytoplasmic export. Regardless of the exact mechanism, these results demonstrate that continuous nuclear import of the c-Rel complex is necessary to maintain constitutive p50-c-Rel activity in WEHI231 cells.

Ikappa Bbeta does not regulate constitutive p50-c-Rel activity. Ikappa Bbeta degradation has been suggested to regulate prolonged NF-kappa B activity induced by extracellular stimuli or constitutive activity induced by infection with the human T-cell leukemia virus type 1 (20, 32, 54). These studies raise the possibility that Ikappa Bbeta degradation also contributes to constitutive p50-c-Rel activity in WEHI231 cells. However, Ikappa Bbeta degradation is relatively slow (half-life of >3 h) and proteasome dependent. Since proteasome inhibitors capable of blocking Ikappa Bbeta degradation do not affect constitutive p50-c-Rel activity, Ikappa Bbeta degradation is not a regulatory contributor for constitutive p50-c-Rel activation.

A study by Suyang et al. (52) suggests that hypophosphorylated Ikappa Bbeta can induce prolonged NF-kappa B activity. Hypophosphorylated Ikappa Bbeta is induced by prolonged stimulation with certain agents, such as LPS or interleukin-1. Prolonged stimulation induces Ikappa Bbeta degradation by proteasome-mediated pathway followed by new synthesis of hypophosphorylated Ikappa Bbeta . In the continual presence of stimuli, newly synthesized Ikappa Bbeta remains hypophosphorylated and is believed to associate with NF-kappa B at a higher affinity than Ikappa Balpha and allow NF-kappa B nuclear translocation. Thus, this form of Ikappa Bbeta is found in the nucleus in association with NF-kappa B and the target DNA binding site (52). If hypophosphorylated Ikappa Bbeta is constitutively produced in unstimulated WEHI231 cells, it may contribute to constitutive p50-c-Rel activity. While this report was under review, a report by the above-cited group demonstrated that WEHI231 cells contained this hypophosphorylated Ikappa Bbeta protein in the nucleus (40). However, our results demonstrate that the majority of detectable Ikappa Bbeta is not hypophosphorylated (Fig. 9A), is cytoplasmic (Fig. 9C), and is associated with c-Rel (Fig. 8C). Although it was also suggested that Ikappa Bbeta degradation is not inhibited by proteasome inhibitors by the same group (40), we were able to block its degradation by various proteasome inhibitors. We were also able to detect Ikappa Balpha mobility shift in Western blots due to S32/36 phosphorylation and multiubiquitination which were not detected by the above-cited investigators in WEHI231 cells. These discrepancies may stem from the differences of procedures used or cell line variation. Our results, however, demonstrate that Ikappa Bbeta is unlikely to play a regulatory role for constitutive p50-c-Rel activity in WEHI231 cells. Furthermore, they suggest an intriguing proteolytic process that induces selective degradation of Ikappa Balpha protein without affecting Ikappa Bbeta proteins, even though both are associated with c-Rel in the cytoplasm of WEHI231 cells. Thus, future investigations aim to define the protease responsible for high basal Ikappa Balpha proteolysis as well as the regulatory mechanism(s) for its activity in WEHI231 cells and in other B cells.

    ACKNOWLEDGMENTS

We thank members of the Verma laboratory, M. Maki, and Z. J. Chen for many discussions. We appreciate R. Wisdom, E. Oltz, E. T. Alarid, and J. Stevenson for critical reading of the manuscript. We also acknowledge P. Chaio for murine Ikappa Balpha cDNA, J. Stevenson for generating pLHL-CAHA and pLHL-CAHA-mIkappa Balpha clones, E. J. Corey for providing lactacystin, M. Maki for E64-d (through Taisho Pharmaceutical), F. Mercurio for ZLLF, R. Naviaux for pCLeco vector, C. Akazawa for CA promoter, and R. J. Ulevitch for 70Z/3-CD14 cells.

This work was funded by a Howard Hughes Medical Institute grant through the UW Medical School and a Shaw Scientist Award from Milwaukee Foundation to S.M. S.D.S. is a trainee under NIH predoctoral training grant T32GM07215.

    FOOTNOTES

* Corresponding author. Mailing address: Program in Cell and Molecular Biology, Department of Human Oncology, K4/554 Clinical Science Center, 600 Highland Ave., Madison, WI 53792. Phone: (608) 262-9281. Fax: (608) 262-8430. E-mail: miyamoto{at}humonc.wisc.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Alkalay, I., A. Yaron, A. Hatzubai, A. Orian, A. Ciechanover, and Y. Ben-Neriah. 1995. Stimulation-dependent Ikappa Balpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 92:10599-10603[Abstract/Free Full Text].
2. Andrews, N. C., and D. V. Faller. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:2499[Free Full Text].
3. Arenzana-Seisdedos, F., J. Thompson, M. S. Rodriguez, F. Bachelerie, D. Thomas, and R. T. Hay. 1995. Inducible nuclear expression of newly synthesized Ikappa Balpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol. Cell. Biol. 15:2689-2696[Abstract].
4. Baeuerle, P. A., and D. Baltimore. 1996. NF-kappa B---ten years after. Cell 87:13-20[Medline].
5. Baldwin, A. S. J. 1996. The NF-kappa B and Ikappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649-683[Medline].
6. Ballard, D. W., W. H. Walker, S. Doerre, P. Sista, J. A. Molitor, E. P. Dixon, N. J. Peffer, M. Hannink, and W. C. Greene. 1990. The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell 63:803-814[Medline].
7. Beg, A. A., and D. Baltimore. 1996. An essential role of NF-kappa B in preventing TNFalpha -induced cell death. Science 274:782-784[Abstract/Free Full Text].
8. Bond, J. S., and P. E. Butler. 1987. Intracellular proteases. Annu. Rev. Biochem. 56:333-364[Medline].
9. Brockman, J. A., D. C. Scherer, T. A. McKinsey, S. M. Hall, X. Qi, W. Y. Lee, and D. W. Ballard. 1995. Coupling of a signal response domain in Ikappa Balpha to multiple pathways for NF-kappa B activation. Mol. Cell. Biol. 15:2809-2818[Abstract].
10. Brown, K., S. Gerstberger, L. Carlson, G. Franzoso, and U. Siebenlist. 1995. Control of Ikappa Balpha proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485-1488[Abstract/Free Full Text].
11. Bunce, C. M., J. A. Thick, J. M. Lord, D. Mills, and G. Brown. 1988. A rapid procedure for isolating hemopoietic cell nuclei. Anal. Biochem. 175:67-73[Medline].
12. Chen, Z., J. Hagler, V. J. Palombella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis. 1995. Signal-induced site-specific phosphorylation targets Ikappa Balpha to the ubiquitin-proteasome pathway. Genes Dev. 9:1586-1597[Abstract/Free Full Text].
13. Chiao, P. J., S. Miyamoto, and I. M. Verma. 1994. Autoregulation of Ikappa Balpha activity. Proc. Natl. Acad. Sci. USA 91:28-32[Abstract/Free Full Text].
14. Ciechanover, A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21[Medline].
15. Croall, D. E., and G. N. Dermartino. 1991. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 71:813-847[Free Full Text].
16. DiDonato, J., F. Mercurio, C. Rosette, J. Wu-Li, H. Suyang, S. Ghosh, and M. Karin. 1996. Mapping of the inducible Ikappa B phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. 16:1295-1304[Abstract].
17. Doi, T. S., T. Takahashi, O. Taguchi, T. Azuma, and Y. Obata. 1997. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J. Exp. Med. 185:953-961[Abstract/Free Full Text].
18. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731[Abstract/Free Full Text].
19. Field, J., J. Nikawa, D. Broek, B. MacDonald, L. Rodgers, I. A. Wilson, R. A. Lerner, and M. Wigler. 1988. Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method. Mol. Cell. Biol. 8:2159-2165[Abstract/Free Full Text].
20. Good, L., and S. C. Sun. 1996. Persistent activation of NF-kappa B/Rel by human T-cell leukemia virus type 1 tax involves degradation of Ikappa Bbeta . J. Virol. 70:2730-2735[Abstract].
21. Griscavage, J. M., S. Wilk, and L. J. Ignarro. 1995. Serine and cysteine proteinase inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene. Biochem. Biophys. Res. Commun. 215:721-729[Medline].
22. Grumont, R. J., I. B. Richardson, C. Gaff, and S. Gerondakis. 1993. rel/NF-kappa B nuclear complexes that bind kappa B sites in the murine c-rel promoter are required for constitutive c-rel transcription in B-cells. Cell Growth Differ. 4:731-743[Abstract].
23. Han, J., J. D. Lee, P. S. Tobias, and R. J. Ulevitch. 1993. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J. Biol. Chem. 268:25009-25014[Abstract/Free Full Text].
24. Imbert, V., R. A. Rupec, A. Livolsi, H. L. Pahl, E. B. M. Traenckner, C. Muellerdieckmann, D. Farahifar, B. Rossi, P. Auberger, P. A. Baeuerle, and J. F. Peyron. 1996. Tyosine phosphorylation of Ikappa Balpha activates NF-kappa B without proteolytic degradation of Ikappa Balpha . Cell 86:787-798[Medline].
25. Inoue, J., L. D. Kerr, A. Kakizuka, and I. M. Verma. 1992. Ikappa Bgamma , a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the Ikappa B family. Cell 68:1109-1120[Medline].
26. Inoue, J., L. D. Kerr, L. J. Ransone, E. Bengal, T. Hunter, and I. M. Verma. 1991. c-rel activates but v-rel suppresses transcription from kappa B sites. Proc. Natl. Acad. Sci. USA 88:3715-3719[Abstract/Free Full Text].
27. Kontgen, F., R. J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9:1965-1977[Abstract/Free Full Text].
28. Kopp, E. B., and S. Ghosh. 1995. NF-kappa B and rel proteins in innate immunity. Adv. Immunol. 58:1-27[Medline].
29. Krappmann, D., F. G. Wulczyn, and C. Scheidereit. 1996. Different mechanisms control signal-induced degradation and basal turnover of the NF-kappa B inhibitor Ikappa Balpha in vivo. EMBO J. 15:6716-6726[Medline].
30. Liou, H. C., G. P. Nolan, S. Ghosh, T. Fujita, and D. Baltimore. 1992. The NF-kappa B p50 precursor, p105, contains an internal Ikappa B-like inhibitor that preferentially inhibits p50. EMBO J. 11:3003-3009[Medline].
31. Liou, H. C., W. C. Sha, M. L. Scott, and D. Baltimore. 1994. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol. Cell. Biol. 14:5349-5359[Abstract/Free Full Text].
32. McKinsey, T. A., J. A. Brockman, D. C. Scherer, S. W. Al-Murrani, P. L. Green, and D. W. Ballard. 1996. Inactivation of Ikappa Bbeta by the tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-kappa B. Mol. Cell. Biol. 16:2083-90[Abstract].
33. Mehdi, S. 1991. Cell-penetrating inhibitors of calpain. Trends Biochem. Sci. 16:150-153[Medline].
34. Miyamoto, S., P. J. Chiao, and I. M. Verma. 1994. Enhanced Ikappa Balpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol. Cell. Biol. 14:3276-3282[Abstract/Free Full Text].
35. Miyamoto, S., M. Maki, M. J. Schmitt, M. Hatanaka, and I. M. Verma. 1994. Tumor necrosis factor alpha -induced phosphorylation of Ikappa Balpha is a signal for its degradation but not dissociation from NF-kappa B. Proc. Natl. Acad. Sci. USA 91:12740-12744[Abstract/Free Full Text].
36. Miyamoto, S., M. J. Schmitt, and I. M. Verma. 1994. Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc. Natl. Acad. Sci. USA 91:5056-5060[Abstract/Free Full Text].
37. Miyamoto, S., and I. M. Verma. 1995. Rel/NF-kappa B/Ikappa B story. Adv. Cancer Res. 66:255-292[Medline].
38. Naviaux, R. K., E. Costanzi, M. Haas, and I. M. Verma. 1996. The pCL vector system-rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70:5701-5705[Abstract/Free Full Text].
39. Palombella, V. J., O. J. Rando, A. L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785[Medline].
40. Phillips, R. J., and S. Ghosh. 1997. Regulation of Ikappa Bbeta in WEHI231 mature B cells. Mol. Cell. Biol. 17:4390-4396[Abstract].
41. Rechsteiner, M., and S. W. Rogers. 1996. PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 21:267-271[Medline].
42. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771[Medline].
43. Rodriguez, M. S., J. Wright, J. Thompson, D. Thomas, F. Baleux, J. L. Virelizier, R. T. Hay, and F. Arenzanaseisdedos. 1996. Identification of lysine residues required for signal-induced ubiquitination and degradtion of Ikappa Balpha in vivo. Oncogene 12:2425-2435[Medline].
44. Saido, T. C., H. Sorimachi, and K. Suzuki. 1994. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 8:814-822[Abstract].
45. Scherer, D. C., J. A. Brockman, H. H. Bendall, G. M. Zhang, D. W. Ballard, and E. M. Oltz. 1996. Corepression of RelA and c-rel inhibits immunoglobulin kappa  gene transcription and rearrangement in precursor B lymphocytes. Immunity 5:563-574[Medline].
46. Schreck, R., and P. A. Baeuerle. 1994. Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-kappa B. Methods Enzymol. 234:151-163[Medline].
47. Schwarz, E. M., D. VanAntwerp, and I. M. Verma. 1996. Constitutive phosphorylation of Ikappa Balpha by casein kinase II occurs preferentially at serine 293: requirement for degradation of free Ikappa Balpha . Mol. Cell. Biol. 16:3554-3559[Abstract].
48. Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705-716[Medline].
49. Sha, W. C., H. C. Liou, E. I. Tuomanen, and D. Baltimore. 1995. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80:321-330[Medline].
50. Snapper, C. M., F. R. Rosas, P. Zelazowski, M. A. Moorman, M. R. Kehry, R. Bravo, and F. Weih. 1996. B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation to Ig secretion and Ig class switching. J. Exp. Med. 184:1537-1541[Abstract/Free Full Text].
51. Sun, S. C., P. A. Ganchi, D. W. Ballard, and W. C. Greene. 1993. NF-kappa B controls expression of inhibitor Ikappa Balpha : evidence for an inducible autoregulatory pathway. Science 259:1912-1915[Abstract/Free Full Text].
52. Suyang, H., R. Phillips, I. Douglas, and S. Ghosh. 1996. Role of unphosphorylated, newly synthesized Ikappa Bbeta in persistent activation of NF-kappa B. Mol. Cell. Biol. 16:5444-5449[Abstract].
53. Ten, R. M., C. V. Paya, N. Israel, O. Le Bail, M. G. Mattei, J. L. Virelizier, P. Kourilsky, and A. Israel. 1992. The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. EMBO J. 11:195-203[Medline].
54. Thompson, J. E., R. J. Phillips, H. Erdjument-Bromage, P. Tempst, and S. Ghosh. 1995. Ikappa Bbeta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 80:573-582[Medline].
55. Tsien, R. Y. 1981. A non-disruptive technique for loading calcium buffers and indicators into cells. Nature 290:527-528[Medline].
56. VanAntwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma. 1996. Suppression of TNFalpha -induced apoptosis by NF-kappa B. Science 274:787-789[Abstract/Free Full Text].
57. VanAntwerp, D. J., and I. M. Verma. 1996. Signal-induced degradation of Ikappa Balpha : association with NF-kappa B and the PEST sequence in Ikappa Balpha are not required. Mol. Cell. Biol. 16:6037-6045[Abstract].
58. Verma, I. M., J. K. Stevenson, E. M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-kappa B/Ikappa B family: intimate tales of association and dissociation. Genes Dev. 9:2723-2735[Free Full Text].
59. Wang, C. Y., M. W. Mayo, and A. S. Baldwin. 1996. TNF- and cancer therapy-induced apoptosis---potentiation by inhibition of NF-kappa B. Science 274:784-787[Abstract/Free Full Text].
60. Whiteside, S. T., J.-C. Epinat, N. R. Rice, and A. Israel. 1997. Ikappa Bvarepsilon , a novel member of the Ikappa B family, controls RelA and cRel NF-kappa B activity. EMBO J. 16:1413-1426[Medline].


Mol Cell Biol, January 1998, p. 19-29, Vol. 18, No. 1
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Chae, J. J., Wood, G., Richard, K., Jaffe, H., Colburn, N. T., Masters, S. L., Gumucio, D. L., Shoham, N. G., Kastner, D. L. (2008). The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-{kappa}B through its N-terminal fragment. Blood 112: 1794-1803 [Abstract] [Full Text]  
  • Biswas, G., Tang, W., Sondheimer, N., Guha, M., Bansal, S., Avadhani, N. G. (2008). A Distinctive Physiological Role for I{kappa}B{beta} in the Propagation of Mitochondrial Respiratory Stress Signaling. J. Biol. Chem. 283: 12586-12594 [Abstract] [Full Text]  
  • Sethi, G., Sung, B., Aggarwal, B. B. (2008). Nuclear Factor-{kappa}B Activation: From Bench to Bedside. Exp. Biol. Med. 233: 21-31 [Abstract] [Full Text]  
  • Souvannavong, V., Saidji, N., Chaby, R. (2007). Lipopolysaccharide from Salmonella enterica Activates NF-{kappa}B through both Classical and Alternative Pathways in Primary B Lymphocytes. Infect. Immun. 75: 4998-5003 [Abstract] [Full Text]  
  • Ashworth, T., Roy, A. L. (2007). Cutting Edge: TFII-I Controls B Cell Proliferation via Regulating NF-{kappa}B. J. Immunol. 178: 2631-2635 [Abstract] [Full Text]  
  • Majdalawieh, A., Zhang, L., Ro, H.-S. (2007). Adipocyte Enhancer-binding Protein-1 Promotes Macrophage Inflammatory Responsiveness by Up-Regulating NF-{kappa}B via I{kappa}B{alpha} Negative Regulation. Mol. Biol. Cell 18: 930-942 [Abstract] [Full Text]  
  • Pani, B., Cornatzer, E., Cornatzer, W., Shin, D.-M., Pittelkow, M. R., Hovnanian, A., Ambudkar, I. S., Singh, B. B. (2006). Up-Regulation of Transient Receptor Potential Canonical 1 (TRPC1) following Sarco(endo)plasmic Reticulum Ca2+ ATPase 2 Gene Silencing Promotes Cell Survival: A Potential Role for TRPC1 in Darier's Disease. Mol. Biol. Cell 17: 4446-4458 [Abstract] [Full Text]  
  • Vigorito, E., Gambardella, L., Colucci, F., McAdam, S., Turner, M. (2005). Vav proteins regulate peripheral B-cell survival. Blood 106: 2391-2398 [Abstract] [Full Text]  
  • Berchtold, C. M., Chen, K.-S., Miyamoto, S., Gould, M. N. (2005). Perillyl Alcohol Inhibits a Calcium-Dependent Constitutive Nuclear Factor-{kappa}B Pathway. Cancer Res. 65: 8558-8566 [Abstract] [Full Text]  
  • Valley, C. C., Metivier, R., Solodin, N. M., Fowler, A. M., Mashek, M. T., Hill, L., Alarid, E. T. (2005). Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor {alpha} N Terminus. Mol. Cell. Biol. 25: 5417-5428 [Abstract] [Full Text]  
  • Wuerzberger-Davis, S. M., Chang, P.-Y., Berchtold, C., Miyamoto, S. (2005). Enhanced G2-M Arrest by Nuclear Factor-{kappa}B-Dependent p21waf1/cip1 Induction. Mol Cancer Res 3: 345-353 [Abstract] [Full Text]  
  • Doerre, S., Mesires, K. P., Daley, K. M., McCarty, T., Knoetig, S., Corley, R. B. (2005). Reductions in I{kappa}B{epsilon} and Changes in NF-{kappa}B Activity during B Lymphocyte Differentiation. J. Immunol. 174: 983-991 [Abstract] [Full Text]  
  • O'Connor, S., Shumway, S., Miyamoto, S. (2005). Inhibition of I{kappa}B{alpha} Nuclear Export as an Approach to Abrogate Nuclear Factor-{kappa}B-Dependent Cancer Cell Survival. Mol Cancer Res 3: 42-49 [Abstract] [Full Text]  
  • O'Connor, S., Shumway, S. D., Amanna, I. J., Hayes, C. E., Miyamoto, S. (2004). Regulation of Constitutive p50/c-Rel Activity via Proteasome Inhibitor-Resistant I{kappa}B{alpha} Degradation in B Cells. Mol. Cell. Biol. 24: 4895-4908 [Abstract] [Full Text]  
  • Aleyasin, H., Cregan, S. P., Iyirhiaro, G., O'Hare, M. J., Callaghan, S. M., Slack, R. S., Park, D. S. (2004). Nuclear Factor-{kappa}B Modulates the p53 Response in Neurons Exposed to DNA Damage. J. Neurosci. 24: 2963-2973 [Abstract] [Full Text]  
  • Nemeth, Z. H., Wong, H. R., Odoms, K., Deitch, E. A., Szabo, C., Vizi, E. S., Hasko, G. (2004). Proteasome Inhibitors Induce Inhibitory {kappa}B (I{kappa}B) Kinase Activation, I{kappa}B{alpha} Degradation, and Nuclear Factor {kappa}B Activation in HT-29 Cells. Mol. Pharmacol. 65: 342-349 [Abstract] [Full Text]  
  • FOWLER, A. M., SOLODIN, N., PREISLER-MASHEK, M. T., ZHANG, P., LEE, A. V., ALARID, E. T. (2004). Increases in estrogen receptor-{alpha} concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J. 18: 81-93 [Abstract] [Full Text]  
  • Waris, G., Livolsi, A., Imbert, V., Peyron, J.-F., Siddiqui, A. (2003). Hepatitis C Virus NS5A and Subgenomic Replicon Activate NF-{kappa}B via Tyrosine Phosphorylation of I{kappa}B{alpha} and Its Degradation by Calpain Protease. J. Biol. Chem. 278: 40778-40787 [Abstract] [Full Text]  
  • De Bosscher, K., Vanden Berghe, W., Haegeman, G. (2003). The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression. Endocr. Rev. 24: 488-522 [Abstract] [Full Text]  
  • Gern, J. E., French, D. A., Grindle, K. A., Brockman-Schneider, R. A., Konno, S.-I., Busse, W. W. (2003). Double-Stranded RNA Induces the Synthesis of Specific Chemokines by Bronchial Epithelial Cells. Am. J. Respir. Cell Mol. Bio. 28: 731-737 [Abstract] [Full Text]  
  • Bernal-Mizrachi, E., Wen, W., Shornick, M., Permutt, M. A. (2002). Activation of Nuclear Factor-{kappa}B by Depolarization and Ca2+ Influx in MIN6 Insulinoma Cells. Diabetes 51: S484-488 [Abstract] [Full Text]  
  • Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D. C., Sonenshein, G. E. (2002). Protein Kinase CK2 Promotes Aberrant Activation of Nuclear Factor-{kappa}B, Transformed Phenotype, and Survival of Breast Cancer Cells. Cancer Res. 62: 6770-6778 [Abstract] [Full Text]  
  • Li, G., Iyengar, R. (2002). Calpain as an effector of the Gq signaling pathway for inhibition of Wnt/beta -catenin-regulated cell proliferation. Proc. Natl. Acad. Sci. USA 99: 13254-13259 [Abstract] [Full Text]  
  • Huang, T. T., Feinberg, S. L., Suryanarayanan, S., Miyamoto, S. (2002). The Zinc Finger Domain of NEMO Is Selectively Required for NF-{kappa}B Activation by UV Radiation and Topoisomerase Inhibitors. Mol. Cell. Biol. 22: 5813-5825 [Abstract] [Full Text]  
  • Witkowski, J. M., Zmuda-Trzebiatowska, E., Swiercz, J. M., Cichorek, M., Ciepluch, H., Lewandowski, K., Bryl, E., Hellmann, A. (2002). Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells. Blood 100: 1802-1809 [Abstract] [Full Text]  
  • Chu, J., Jeffries, S., Norton, J. E., Capobianco, A. J., Bresnick, E. H. (2002). Repression of Activator Protein-1-mediated Transcriptional Activation by the Notch-1 Intracellular Domain. J. Biol. Chem. 277: 7587-7597 [Abstract] [Full Text]  
  • Gasparian, A. V., Yao, Y. J., Kowalczyk, D., Lyakh, L. A., Karseladze, A., Slaga, T. J., Budunova, I. V. (2002). The role of IKK in constitutive activation of NF-{kappa}B transcription factor in prostate carcinoma cells. J. Cell Sci. 115: 141-151 [Abstract] [Full Text]  
  • Shumway, S. D., Berchtold, C. M., Gould, M. N., Miyamoto, S. (2002). Evidence for Unique Calmodulin-Dependent Nuclear Factor-kappa B Regulation in WEHI-231 B Cells. Mol. Pharmacol. 61: 177-185 [Abstract] [Full Text]  
  • Shen, J., Channavajhala, P., Seldin, D. C., Sonenshein, G. E. (2001). Phosphorylation by the Protein Kinase CK2 Promotes Calpain-Mediated Degradation of I{kappa}B{alpha}. J. Immunol. 167: 4919-4925 [Abstract] [Full Text]  
  • Tsuji, S., Okamoto, M., Yamada, K., Okamoto, N., Goitsuka, R., Arnold, R., Kiefer, F., Kitamura, D. (2001). B Cell Adaptor Containing Src Homology 2 Domain (BASH) Links B Cell Receptor Signaling to the Activation of Hematopoietic Progenitor Kinase 1. JEM 194: 529-540 [Abstract] [Full Text]  
  • Huang, T. T., Miyamoto, S. (2001). Postrepression Activation of NF-{kappa}B Requires the Amino-Terminal Nuclear Export Signal Specific to I{kappa}B{alpha}. Mol. Cell. Biol. 21: 4737-4747 [Abstract] [Full Text]  
  • Tam, W. F., Wang, W., Sen, R. (2001). Cell-Specific Association and Shuttling of I{kappa}B{alpha} Provides a Mechanism for Nuclear NF-{kappa}B in B Lymphocytes. Mol. Cell. Biol. 21: 4837-4846 [Abstract] [Full Text]  
  • Stramer, B. M., Cook, J. R., Fini, M. E., Taylor, A., Obin, M. (2001). Induction of the Ubiquitin-Proteasome Pathway during the Keratocyte Transition to the Repair Fibroblast Phenotype. IOVS 42: 1698-1706 [Abstract] [Full Text]  
  • Jaspers, I., Zhang, W., Fraser, A., Samet, J. M., Reed, W. (2001). Hydrogen Peroxide Has Opposing Effects on IKK Activity and Ikappa Balpha Breakdown in Airway Epithelial Cells. Am. J. Respir. Cell Mol. Bio. 24: 769-777 [Abstract] [Full Text]  
  • Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D. C., Traish, A. M., Mercurio, F., Sonenshein, G. E. (2001). Roles of IKK Kinases and Protein Kinase CK2 in Activation of Nuclear Factor-{{kappa}}B in Breast Cancer. Cancer Res. 61: 3810-3818 [Abstract] [Full Text]  
  • Pennington, K. N., Taylor, J. A., Bren, G. D., Paya, C. V. (2001). I{kappa}B Kinase-Dependent Chronic Activation of NF-{kappa}B Is Necessary for p21WAF1/Cip1 Inhibition of Differentiation-Induced Apoptosis of Monocytes. Mol. Cell. Biol. 21: 1930-1941 [Abstract] [Full Text]  
  • Chen, F., Demers, L. M., Vallyathan, V., Lu, Y., Castranova, V., Shi, X. (2000). Impairment of NF-kappa B activation and modulation of gene expression by calpastatin. Am. J. Physiol. Cell Physiol. 279: C709-C716 [Abstract] [Full Text]  
  • Fields, E. R., Seufzer, B. J., Oltz, E. M., Miyamoto, S. (2000). A Switch in Distinct I{kappa}B{alpha} Degradation Mechanisms Mediates Constitutive NF-{kappa}B Activation in Mature B Cells. J. Immunol. 164: 4762-4767 [Abstract] [Full Text]  
  • Schoonbroodt, S., Ferreira, V., Best-Belpomme, M., Boelaert, J. R., Legrand-Poels, S., Korner, M., Piette, J. (2000). Crucial Role of the Amino-Terminal Tyrosine Residue 42 and the Carboxyl-Terminal PEST Domain of I{kappa}B{alpha} in NF-{kappa}B Activation by an Oxidative Stress. J. Immunol. 164: 4292-4300 [Abstract] [Full Text]  
  • Huang, T. T., Wuerzberger-Davis, S. M., Seufzer, B. J., Shumway, S. D., Kurama, T., Boothman, D. A., Miyamoto, S. (2000). NF-kappa B Activation by Camptothecin. A LINKAGE BETWEEN NUCLEAR DNA DAMAGE AND CYTOPLASMIC SIGNALING EVENTS. J. Biol. Chem. 275: 9501-9509 [Abstract] [Full Text]  
  • Huang, T. T., Kudo, N., Yoshida, M., Miyamoto, S. (2000). A nuclear export signal in the N-terminal regulatory domain of Ikappa Balpha controls cytoplasmic localization of inactive NF-kappa B/Ikappa Balpha complexes. Proc. Natl. Acad. Sci. USA 97: 1014-1019 [Abstract] [Full Text]  
  • Xia, Y., Chen, S., Wang, Y., Mackman, N., Ku, G., Lo, D., Feng, L. (1999). RelB Modulation of Ikappa Balpha Stability as a Mechanism of Transcription Suppression of Interleukin-1alpha (IL-1alpha ), IL-1beta , and Tumor Necrosis Factor Alpha in Fibroblasts. Mol. Cell. Biol. 19: 7688-7696 [Abstract] [Full Text]  
  • Shumway, S. D., Maki, M., Miyamoto, S. (1999). The PEST Domain of Ikappa Balpha Is Necessary and Sufficient for in Vitro Degradation by {micro}-Calpain. J. Biol. Chem. 274: 30874-30881 [Abstract] [Full Text]  
  • Doerre, S., Corley, R. B. (1999). Constitutive Nuclear Translocation of NF-{kappa}B in B Cells in the Absence of I{kappa}B Degradation. J. Immunol. 163: 269-277 [Abstract] [Full Text]  
  • Welm, A. L., Timchenko, N. A., Darlington, G. J. (1999). C/EBPalpha Regulates Generation of C/EBPbeta Isoforms through Activation of Specific Proteolytic Cleavage. Mol. Cell. Biol. 19: 1695-1704 [Abstract] [Full Text]  
  • Han, Y., Weinman, S., Boldogh, I., Walker, R. K., Brasier, A. R. (1999). Tumor Necrosis Factor-alpha -inducible Ikappa Balpha Proteolysis Mediated by Cytosolic m-Calpain. A MECHANISM PARALLEL TO THE UBIQUITIN-PROTEASOME PATHWAY FOR NUCLEAR FACTOR-kappa B ACTIVATION. J. Biol. Chem. 274: 787-794 [Abstract] [Full Text]  
  • Cheng, J. D., Ryseck, R.-P., Attar, R. M., Dambach, D., Bravo, R. (1998). Functional Redundancy of the Nuclear Factor kappa B Inhibitors Ikappa Balpha and Ikappa Bbeta. JEM 188: 1055-1062 [Abstract] [Full Text]  
  • Cuervo, A. M., Hu, W., Lim, B., Dice, J. F. (1998). Ikappa B Is a Substrate for a Selective Pathway of Lysosomal Proteolysis. Mol. Biol. Cell 9: 1995-2010 [Abstract] [Full Text]  
  • Lam, L. T., Ronchini, C., Norton, J., Capobianco, A. J., Bresnick, E. H. (2000). Suppression of Erythroid but Not Megakaryocytic Differentiation of Human K562 Erythroleukemic Cells by Notch-1. J. Biol. Chem. 275: 19676-19684 [Abstract] [Full Text]  
  • Kouba, D. J., Nakano, H., Nishiyama, T., Kang, J., Uitto, J., Mauviel, A. (2001). Tumor Necrosis Factor-alpha Induces Distinctive NF-kappa B Signaling within Human Dermal Fibroblasts. J. Biol. Chem. 276: 6214-6224 [Abstract] [Full Text]  
  • Petranka, J., Wright, G., Forbes, R. A., Murphy, E. (2001). Elevated Calcium in Preneoplastic Cells Activates NF-kappa B and Confers Resistance to Apoptosis. J. Biol. Chem. 276: 37102-37108 [Abstract] [Full Text]  
  • Yin, L., Laevsky, G., Giardina, C. (2001). Butyrate Suppression of Colonocyte NF-kappa B Activation and Cellular Proteasome Activity. J. Biol. Chem. 276: 44641-44646 [Abstract] [Full Text]  
  • Preisler-Mashek, M. T., Solodin, N., Stark, B. L., Tyriver, M. K., Alarid, E. T. (2002). Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am. J. Physiol. Endocrinol. Metab. 282: E891-E898 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyamoto, S.
Right arrow Articles by Shumway, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyamoto, S.
Right arrow Articles by Shumway, S. D.